Dynavax Technologies Corp at JPMorgan Healthcare Conference Transcript
Hi, everyone, welcome. In terms of logistics, we're going to run through the presentation and then open it up for Q&A without much further ado, pleasue to present Dynamax.
Thank you, Luca, and thank you for JPMorgan for allowing us to present today. I'm Ryan Spencer, the CEO of Dynavax. And before I begin, I'll remind you all that we're going to make some forward-looking statements today that contain some risks and uncertainties that are detailed in our Forms 10-Q and 10-K filings, which I encourage you all to read.
Just to start off a little bit about Dynavax and who we are. We are a vaccine company focused on developing novel vaccines that help protect the world against infectious disease. We've had pretty good advancement in our core business over the last few years, which I will walk us through here.
First, our pipeline, our portfolio of assets are basically built on the backbone of our core technology, which is TLR biology, utilizing TLR9 to over the course of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |